Ali Ataya, MD - Research

Research at a glance

Top areas of exploration

Dyspnea , 14 publications
Hypertension, Pulmonary , 6 publications
Pulmonary Alveolar Proteinosis , 5 publications
Lung , 5 publications

Research activity

116 publications

405 citations

Why is this important?

Active clinical trials

IMPALA-2

160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim or placebo for 48 weeks. Subjects completing the 48 week placebo-controlled period will receive鈥�

Investigator: Ali Ataya
Status: Accepting Candidates
Ages: 18 Years - N/A
Sexes: All

ROR-PH-303 (APD811-303)

Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.

Investigator: Ali Ataya
Status: Accepting Candidates
Ages: 18 Years - N/A
Sexes: All

United therapeutics 301

Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO)鈥�

Investigator: Ali Ataya
Status: Accepting Candidates
Ages: 18 Years - N/A
Sexes: All

My publications

116 publications

2022

Pulmonary renal syndrome: a clinical review.

Breathe (Sheffield, England)

鈥�

2021

A 29-Year-Old Woman With Cough, Dry Eyes, Pulmonary Cysts, and Nodules.

Chest

鈥�

2021

A 44-Year-Old Woman With Multiple Neoplasms and Cystic Lung Disease.

Chest

鈥�

2021

A 60-Year-Old Man With Dyspnea, Proximal Muscle Weakness, and Pulmonary Arterial Hypertension.

Chest

鈥�

2021

Emerging Medical Therapies for Pulmonary Alveolar Proteinosis.

American journal of respiratory and critical care medicine

鈥�

BOB体育